The BCNT treatment planning for the Brookhaven trials on human gliomas

Journal Article · Sun Dec 31 04:00:00 EST 1995 · Transactions of the American Nuclear Society

OSTI ID:411516

Capala, J ^[1]; Wheeler, F J; Wessol, D E ^[2]; Chadha, M ^[3]

---

1. Brookhaven National Laboratory, Upton, NY (United States)
2. Idaho National Engineering Laboratory, Idaho Falls, ID (United States)
3. Beth Israel Medical Center, New York, NY (United States)

Boron neutron capture therapy (BNCT) trials for human glioma (glioblastoma multiform) were initiated September 1994 at the Brookhaven National Laboratory (BNL). Patients are given p-boronophenylalanine-fructose (BPA-F) intravenously as the boron carrier followed by exposure to the epithermal-neutron beam at the Brookhaven Medical Research Reactor (BMRR). The initial phase of the study is to determine safety and toxicity of the drug and irradiation procedure. The epithermal-neutron beam was developed in a joint effort by BNL and Idaho National Engineering Laboratory (INEL) researchers. For the human trials, treatment planning and radiation dose estimation is performed using the BNCT-Rtpe and the rtt-MC computer codes developed by the INEL BNCT program. This paper discusses our initial experience using these treatment planning codes for human subjects. The basic principles of BNCT have been previously documented.

• OSTI ID: 411516
• Report Number(s): CONF-951006--
• Journal Information: Transactions of the American Nuclear Society, Journal Name: Transactions of the American Nuclear Society Vol. 73; ISSN 0003-018X; ISSN TANSAO
• Country of Publication: United States
• Language: English

Related Subjects

55 BIOLOGY AND MEDICINE
BASIC STUDIES
99 GENERAL AND MISCELLANEOUS
B CODES
BORON 10
FRUCTOSE
GLIOMAS
LABELLED COMPOUNDS
M CODES
MAN
NEUTRON CAPTURE THERAPY
PATIENTS
PHENYLALANINE
RADIATION DOSES
RADIOPHARMACEUTICALS
TOXICITY